"Cytarabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
| Descriptor ID |
D003561
|
| MeSH Number(s) |
D03.383.742.680.245.453 D13.570.065.300 D13.570.685.245.453
|
| Concept/Terms |
Cytarabine- Cytarabine
- Arabinofuranosylcytosine
- Aracytidine
- Cytosine Arabinoside
- Arabinoside, Cytosine
- Arabinosylcytosine
Cytosar- Cytosar
- Cytosar-U
- Cytosar U
- CytosarU
|
Below are MeSH descriptors whose meaning is more general than "Cytarabine".
Below are MeSH descriptors whose meaning is more specific than "Cytarabine".
This graph shows the total number of publications written about "Cytarabine" by people in this website by year, and whether "Cytarabine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 1 | 1 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 4 | 4 |
| 2002 | 0 | 4 | 4 |
| 2003 | 2 | 5 | 7 |
| 2004 | 4 | 5 | 9 |
| 2005 | 1 | 1 | 2 |
| 2006 | 2 | 2 | 4 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 4 | 6 |
| 2009 | 2 | 2 | 4 |
| 2010 | 0 | 7 | 7 |
| 2011 | 0 | 4 | 4 |
| 2012 | 2 | 4 | 6 |
| 2013 | 2 | 4 | 6 |
| 2014 | 0 | 3 | 3 |
| 2015 | 1 | 1 | 2 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 1 | 2 |
| 2019 | 2 | 2 | 4 |
| 2020 | 2 | 5 | 7 |
| 2021 | 0 | 2 | 2 |
| 2023 | 1 | 2 | 3 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytarabine" by people in Profiles.
-
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial. Blood Adv. 2024 04 23; 8(8):2020-2029.
-
Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2024 Jan; 65(1):69-77.
-
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia. 2024 01; 38(1):58-66.
-
Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy. Adv Sci (Weinh). 2023 08; 10(23):e2300445.
-
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. Blood. 2023 01 12; 141(2):156-167.
-
Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis. Br J Haematol. 2021 11; 195(3):e138-e141.
-
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Adv. 2021 07 13; 5(13):2775-2787.
-
Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). Am J Clin Pathol. 2020 11 04; 154(6):731-741.
-
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020 12; 26(12):1852-1858.
-
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Am J Hematol. 2020 12; 95(12):1457-1465.